MwanzoNVV1 • FRA
add
Novavax Inc
Bei iliyotangulia
€ 7.18
Bei za siku
€ 7.27 - € 7.43
Bei za mwaka
€ 4.56 - € 9.24
Thamani ya kampuni katika soko
1.41B USD
Wastani wa hisa zilizouzwa
elfu 1.94
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
MoneyCheck
saa 21 zilizopita
Novavax (NVAX) Stock: Analysts See 132% Upside as Sanofi Deal Takes Shape
11.87%
2.39%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 70.44M | -16.64% |
Matumizi ya uendeshaji wa biashara | 46.12M | -42.92% |
Mapato halisi | -202.38M | -66.84% |
Kiwango cha faida halisi | -287.29 | -100.16% |
Mapato kwa kila hisa | -1.25 | -64.47% |
EBITDA | -72.80M | 37.84% |
Asilimia ya kodi ya mapato | 0.32% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 762.89M | -16.12% |
Jumla ya mali | 1.18B | -31.10% |
Jumla ya dhima | 1.34B | -40.30% |
Jumla ya hisa | -156.67M | — |
hisa zilizosalia | 162.50M | — |
Uwiano wa bei na thamani | -7.48 | — |
Faida inayotokana na mali | -15.77% | — |
Faida inayotokana mtaji | -110.07% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -202.38M | -66.84% |
Pesa kutokana na shughuli | 107.80M | 174.44% |
Pesa kutokana na uwekezaji | -136.53M | -527.83% |
Pesa kutokana na ufadhili | 42.44M | 43,854.64% |
Mabadiliko halisi ya pesa taslimu | 14.38M | 113.44% |
Mtiririko huru wa pesa | 96.84M | 223.39% |
Kuhusu
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company is also developing vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1987
Makao Makuu
Tovuti
Wafanyakazi
952
